brivaracetam (Briviact)
Jump to navigation
Jump to search
Indications
- adjunctive therapy for partial seizures (focal epilepsy) in patients >= 16 years[1]
Adverse effects
- most common
- serious
- rare
Laboratory
Notes
- marketed by UCB, Inc. of Smyrna, Georgia.
More general terms
References
- ↑ 1.0 1.1 FDA News Release. February 19, 2016 FDA approves Briviact to treat partial onset seizures http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm